Komodo market SignalsTirzepatide Patients Were 83% Less Likely to Start CPAP Therapy.

Following FDA approval of tirzepatide for obstructive sleep apnea, Komodo tracked real-world treatment patterns across several million de-identified patients. What emerged was a measurable shift in device utilization, visible in claims data months before it appears in quarterly reporting.

This is the first edition of Komodo Market Signals, a monthly series that tracks observable changes in real-world treatment behavior before they appear in quarterly results.

What’s in This Edition:

• CPAP initiation and engagement patterns following tirzepatide uptake
• Timing of treatment initiation relative to OSA diagnosis
• Payer mix and age distribution among tirzepatide users
• Provider specialty breakdown across 84% of new prescriptions
• Tirzepatide uptake in OSA patients is shifting device utilization patterns in ways that quarterly reporting hasn’t yet captured

For informational purposes only. Does not constitute investment advice.